Integrated pharmacokinetic and metabolic modeling of ipriflavone and metabolites after oral administration

American Journal of Therapeutics

Volumn 4, Issue 5-6, 1997, Pages 189-198

  Rohatagi, Shashank ^a   Barrett, Jeffrey S ^a,b  

^a Somerset Pharmaceuticals   (United States)

^b DUPONT COMPANY   (United States)

Author keywords

Ipriflavone; Oral; Pharmacokinetic model

Indexed keywords

IPRIFLAVONE;

ARTICLE; CALCULATION; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG METABOLISM; PRIORITY JOURNAL; URINARY EXCRETION;

EID: 0030940231     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/00045391-199705000-00005     Document Type: Article

References (24)

1. Brandi ML: Flavonoids; biochemical effects and therapeutic applications. Bone Miner 1992;19(suppl):S3-S14.
2. Yoshida K, Tsukomoto T, Torii H, et al.: Disposition of ipriflavone (TC-80) in rats and dogs. Radioisotopes 1985; 34:618-623.
3. Yamazaki I, Shino A, Shimuzu Y, et al.: Effect of ipriflavone on glucocorticoid-induced osteoporosis in rats. Life Sci 1986;951-958.
4. Yamazaki I, Shino A, Tsukuda R: Effect of ipriflavone on osteoporosis induced by overactemy in rats. J Bone Miner Metab 1986;3:205-210.
5. Shino A, Mutsuo T, Tsuda M, et al.: Effect of ipriflavone on bone and mineral metabolism in streptozotocin diabetic rats. J Bone Miner Metab 1986;3:27-37.
6. Tsuda M, Kitazaki T, Ito T, Fujita T: The effects of ipriflavone (TC-80) on the bone resorption in tissue culture. J Bone Miner Res 1987;1:207-211.
7. Benvenuti S, Tanini A, Frediani U, et al.: Effects of iprifalvone and its metabolites on a clonal oesteoblasic cell line. J Bone Miner Res 1991;6:987-995.
8. Levai F, Szatmari I: The metabolism of ipriflavone. Acta Pharmaceutica Hungarica. 1995;65(6):215-218.
9. Saito AM: Pharmacokinetic study of ipriflavone (TC-80) by oral administration in healthy male volunteers. Jpn Pharm Ther J 1985;13:7223-7233.
10. Sato T, Koite T, Hamada A, et al.: Pharmacokinetics of ipriflavone tablets in long-term administration to patients with osteoporosis. Jpn Pharm Ther J 1986;14:7630-7634.
11. Yoshida K, Tsukomoto T, Torii H, et al.: Metabolism of ipriflavone (TC-80) in rats. Radioisotopes 1985;34:612-617.
12. Suda A: Effect of parathyroid hormone on the parietal bones of rats, and effects of ipriflavone. J Bone Miner Metab 1987;5:51-56.
13. Levai F, Szatmari I: The pharmacokinetics of ipriflavone. Acta Pharmaceutica Hungarica. 1995;65(6):219-222.
14. Monostory K, Vereczkey L: Interaction of theophylline and ipriflavone at the P450 level. Eur J Drug Met Pharmacokin 1995;20(1):43-47.
15. Gibaldi M and Perrier D (eds.): Pharmacokinetics. Marcel Dekker, New York, 2nd edition, 1982.
16. Wagner JG: Pharmacokinetics for the Pharmaceutical Scientist. Technomic Publishing Co., PA, 1993.
17. Klippert PJM, Noordhoek J: The area under the curve of metabolites for drugs and metabolites cleared by the liver and extrahepatic organs: its dependence on the administration route of precursor drug. Drug Met Disp 1985;13(1):97-101.
18. Houston JB, Taylor G: Drug metabolite concentration-time profiles: influence of route of drug administration. Br J Clin Pharmac 1984;17:385-394.
19. Rohatagi S, Barrett JS, Sawyers W: Pharmacokinetics of ipriflavone and metabolites after oral administration of a corn oil suspension relative to the Osteofix tablet. Am J Ther, in press.
20. Scientist, Micromath User's Handbook, Salt Lake City, Utah, 1995.
21. Yu K, Sawyers W, DeWitt K, et al.: The analysis of ipriflavone and its five metabolites in human plasma by HPLC. Pharm Res 1995;2(suppl):S-46.
22. SAS Institute; Cary, N.C.
23. Lam FC, Hung CT, Perrier DG: Estimation of variance for harmonic mean half-lives. J Pharm Sci 1985;74(2): 229-231.
24. Rohatagi S, Barrett JS, DeWitt KE, Morales RJ: Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration. Biopharm Drug Disposit, in press.